DDInter1628 DDInter1750
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020.
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tazemetostat
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tazemetostat
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tazemetostat
Ruxolitinib {u} (Compound) upregulates {v} (Gene) KLHL18
KLHL18 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tazemetostat
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Ruxolitinib {u} (Compound) upregulates {v} (Gene) KLHL18
KLHL18 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Ruxolitinib {u} (Compound) binds {v} (Gene) PHKG2
PHKG2 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tazemetostat
Ruxolitinib {u} (Compound) upregulates {v} (Gene) RLF
RLF {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Tazemetostat
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Ruxolitinib (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Ruxolitinib (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Ruxolitinib (Compound) upregulates KLHL18 (Gene) and KLHL18 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Ruxolitinib (Compound) upregulates KLHL18 (Gene) and KLHL18 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Ruxolitinib (Compound) binds PHKG2 (Gene) and PHKG2 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Ruxolitinib (Compound) upregulates RLF (Gene) and RLF (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Tazemetostat